|
All patients (N = 71)
|
BRAF WT (N = 39)
|
BRAF MUT (N = 25)
|
---|
BDX008+ (N = 30)
|
BDX008- (N = 41)
|
BDX008+ (N = 15)
|
BDX008- (N = 24)
|
BDX008+ (N = 12)
|
BDX008- (N = 13)
|
---|
Age
|
Median (Range)
|
59 (28–86)
|
66 (32–80)
|
59 (34–86)
|
61 (44–80)
|
52 (29–69)
|
67 (32–78)
|
Gender, n (%)
|
Female
|
16 (53)
|
19 (46)
|
8 (53)
|
10 (42)
|
7 (58)
|
7 (54)
|
Male
|
14 (47)
|
22 (54)
|
7 (47)
|
14 (58)
|
5 (42)
|
6 (46)
|
BRAF Status, n (%)
|
Mutation
|
12 (40)
|
13 (32)
|
0 (0)
|
0 (0)
|
12 (100)
|
13 (100)
|
Wild Type
|
15 (50)
|
24 (59)
|
15(100)
|
24(100)
|
0 (0)
|
0 (0)
|
NA
|
3 (10)
|
4 (10)
|
0 (0)
|
0 (0)
|
0 (0)
|
0 (0)
|
Line of Therapy with anti-PD-1, n (%)
|
1st
|
1 (3)
|
0 (0)
|
0 (0)
|
0 (0)
|
0 (0)
|
0 (0)
|
2nd
|
4(13)
|
13 (32)
|
3 (20)
|
9 (38)
|
0 (0)
|
3 (23)
|
3rd
|
17(57)
|
16 (39)
|
11 (73)
|
11 (46)
|
5 (42)
|
3 (23)
|
4th
|
4 (13)
|
10 (24)
|
1 (7)
|
4 (17)
|
3 (25)
|
6 (46)
|
5th and higher
|
4 (13)
|
2 (5)
|
0 (0)
|
0 (0)
|
4 (33)
|
1(8)
|
Targeted therapy, n (%)
|
No
|
18 (60)
|
28 (68)
|
14 (93)
|
22 (92)
|
2 (15)
|
1 (8)
|
Yes
|
12 (40)
|
13 (32)
|
1 (7)
|
2 (8)
|
11 (85)
|
11 (92)
|
Anti-PD-1 agent, n (%)
|
Nivolumab
|
9 (30)
|
15 (37)
|
6 (40)
|
10 (42)
|
1 (8)
|
4 (31)
|
Pembrolizumab
|
21 (70)
|
26 (62)
|
9 (60)
|
14 (58)
|
11 (92)
|
9 (69)
|
NLR, n (%)
|
<5
|
25 (83)
|
19 (46)
|
14 (93)
|
12 (50)
|
8 (67)
|
5 (38)
|
≥5
|
5 (17)
|
22 (54)
|
1 (7)
|
12 (50)
|
4 (33)
|
8 (62)
|
LDH
|
Median (in IU/l)
|
402
|
617
|
379
|
525
|
416
|
728
|
NA, n (%)
|
5 (17)
|
2 (5)
|
3 (20)
|
2 (8)
|
2 (17)
|
0 (0)
|
<2ULNa, n (%)
|
22 (73)
|
21 (51)
|
12 (80)
|
15 (63)
|
7 (58)
|
5 (38)
|
2ULNa, n (%)
|
3 (10)
|
18 (44)
|
0 (0)
|
7 (29)
|
3 (25)
|
8 (62)
|
Melanoma Type, n (%)
|
cutaneous
|
22 (73)
|
24 (59)
|
11 (73)
|
14 (58)
|
10 (83)
|
9 (69)
|
mucosal
|
2 (7)
|
1 (2)
|
2 (13)
|
1 (4)
|
0 (0)
|
0 (0)
|
SPI
|
2 (7)
|
2 (5)
|
1 (7)
|
1 (4)
|
1 (8)
|
0 (0)
|
uveal
|
2 (7)
|
4 (10)
|
0 (0)
|
3 (13)
|
0 (0)
|
0 (0)
|
NA
|
2 (7)
|
10 (24)
|
1 (7)
|
5 (21)
|
1 (8)
|
4 (31)
|
- aULN upper limit of normal (333 IU/l)